Your browser doesn't support javascript.
loading
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.
Ng, Heng Joo; Alata, Maaz Kamal; Nguyen, Quang The; Huynh Duc Vinh, Phu; Tan, Jing Yuan; Wong, Chieh Lee.
Afiliación
  • Ng HJ; Department of Haematology, Singapore General Hospital, Singapore, Singapore.
  • Alata MK; Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
  • Nguyen QT; Stem Cell Transplantation Department, Blood Transfusion Hematology Hospital, Ho Chi Minh, Vietnam.
  • Huynh Duc Vinh P; Stem Cell Transplantation Department, Blood Transfusion Hematology Hospital, Ho Chi Minh, Vietnam.
  • Tan JY; Department of Haematology, Singapore General Hospital, Singapore, Singapore.
  • Wong CL; Department of Haematology, Sunway Medical Centre, Bandar Sunway, Selangor, Malaysia. wongcl@sunmed.com.my.
Clin Exp Med ; 24(1): 119, 2024 Jun 04.
Article en En | MEDLINE | ID: mdl-38833206
ABSTRACT
Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / COVID-19 Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Exp Med Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Singapur

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / COVID-19 Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Exp Med Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Singapur